Pulmonary hypertension complicating sarcoidosis

Presse Medicale

Volumn 41, Issue 6 PART 2, 2012, Pages

  Nunes, Hilario ^a   Uzunhan, Yurdagul ^a   Freynet, Olivia ^a   Humbert, Marc ^b   Brillet, Pierre Yves ^a   Kambouchner, Marianne ^a   Valeyre, Dominique ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; ILOPROST; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL;

BLOOD VESSEL REACTIVITY; COMORBIDITY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOPPLER ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HUMAN; LUNG BLOOD VESSEL; LUNG FUNCTION TEST; OXYGEN THERAPY; PATHOGENESIS; PORTAL HYPERTENSION; PROGNOSIS; PULMONARY HYPERTENSION; SARCOIDOSIS; SHORT SURVEY; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 84861948213     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.04.003     Document Type: Short Survey

References (85)

1. Iannuzzi M.C., Rybicki B.A., Teirstein A.S. Sarcoidosis. N Engl J Med 2007, 357:2153-2165.
2. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54:S43-S54.
3. Galie N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34:1219-1263.
4. Battesti J.P., Georges R., Basset F., Saumon G. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax 1978, 33:76-84.
5. Gluskowski J., Hawrylkiewicz I., Zych D., Wojtczak A., Zielinski J. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration 1984, 46:26-32.
6. Handa T., Nagai S., Miki S., et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006, 129:1246-1252.
7. Mayock R.L., Bertrand P., Morrison C.E., Scott J.H. Manifestations of Sarcoidosis. Analysis of 145 patients, with a review of nine series selected from the literature. Am J Med 1963, 35:67-89.
8. Rizzato G., Pezzano A., Sala G., et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur J Respir Dis 1983, 64:121-128.
9. Shorr A.F., Helman D.L., Davies D.B., Nathan S.D. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005, 25:783-788.
10. Baughman R.P., Engel P.J., Meyer C.A., Barrett A.B., Lower E.E. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23:108-116.
11. Baughman R.P., Engel P.J., Taylor L., Lower E.E. Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010, 138(5):1078-1085.
12. Bourbonnais J.M., Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008, 32:296-302.
13. Nunes H., Humbert M., Capron F., et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006, 61:68-74.
14. Sulica R., Teirstein A.S., Kakarla S., Nemani N., Behnegar A., Padilla M.L. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005, 128:1483-1489.
15. Barnett C.F., Bonura E.J., Nathan S.D., et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009, 135:1455-1461.
16. Emirgil C., Sobol B.J., Herbert W.H., Trout K. The lesser circulation in pulmonary fibrosis secondary to sarcoidosis and its relationship to respiratory function. Chest 1971, 60:371-378.
17. Shorr A.F., Davies D.B., Nathan S.D. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002, 122:233-238.
18. Preston I.R., Klinger J.R., Landzberg M.J., Houtchens J., Nelson D., Hill N.S. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001, 120:866-872.
19. Rosen Y., Moon S., Huang C.T., Gourin A., Lyons H.A. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med 1977, 101:170-174.
20. Takemura T., Matsui Y., Saiki S., Mikami R. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol 1992, 23:1216-1223.
21. Kambouchner M., Pirici D., Uhl J.F., Mogoanta L., Valeyre D., Bernaudin J.F. Lymphatic and blood microvasculature organisation in pulmonary sarcoid granulomas. Eur Respir J 2011, 37:835-840.
22. Hoffstein V., Ranganathan N., Mullen J.B. Sarcoidosis simulating pulmonary veno-occlusive disease. Am Rev Respir Dis 1986, 134:809-811.
23. Jones R.M., Dawson A., Jenkins G.H., Nicholson A.G., Hansell D.M., Harrison N.K. Sarcoidosis-related pulmonary veno-occlusive disease presenting with recurrent haemoptysis. Eur Respir J 2009, 34:517-520.
24. Fartoukh M., Humbert M., Capron F., et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000, 161:216-223.
25. Milman N., Svendsen C.B., Iversen M., Videbaek R., Carlsen J. Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil. Clin Respir J 2009, 3:207-213.
26. Fisher K.A., Serlin D.M., Wilson K.C., Walter R.E., Berman J.S., Farber H.W. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006, 130:1481-1488.
27. Sofia M., Mormile M., Faraone S., Alifano M., Carratu P., Carratu L. Endothelin-1 excretion in urine in active pulmonary sarcoidosis and in other interstitial lung diseases. Sarcoidosis 1995, 12:118-123.
28. Letizia C., Danese A., Reale M.G., et al. Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva Med 2001, 43:257-261.
29. Reichenberger F., Schauer J., Kellner K., Sack U., Stiehl P., Winkler J. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 2001, 179:163-174.
30. Terashita K., Kato S., Sata M., Inoue S., Nakamura H., Tomoike H. Increased endothelin-1 levels of BAL fluid in patients with pulmonary sarcoidosis. Respirology 2006, 11:145-151.
31. Shahar I., Fireman E., Topilsky M., et al. Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol 1999, 21:759-775.
32. Hamilton-Craig C.R., Slaughter R., McNeil K., Kermeen F., Walters D.L. Improvement after angioplasty and stenting of pulmonary arteries due to sarcoid mediastinal fibrosis. Heart Lung Circ 2009, 18:222-225.
33. Toonkel R.L., Borczuk A.C., Pearson G.D., Horn E.M., Thomashow B.M. Sarcoidosis-associated fibrosing mediastinitis with resultant pulmonary hypertension: a case report and review of the literature. Respiration 2010, 79:341-345.
34. Salazar A., Mana J., Sala J., Landoni B.R., Manresa F. Combined portal and pulmonary hypertension in sarcoidosis. Respiration 1994, 61:117-119.
35. Nunes H., Freynet O., Naggara N., et al. Cardiac sarcoidosis. Semin Respir Crit Care Med 2010, 31:428-441.
36. Angomachalelis N., Hourzamanis A., Vamvalis C., Gavrielides A. Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic sarcoidosis. Postgrad Med J 1992, 68(Suppl. 1):S52-S56.
37. Fahy G.J., Marwick T., McCreery C.J., Quigley P.J., Maurer B.J. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 1996, 109:62-66.
38. Crawshaw A.P., Wotton C.J., Yeates D.G., Goldacre M.J., Ho L.P. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax 2011, 66:447-448.
39. Swigris J.J., Olson A.L., Huie T.J., et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest 2011, 140:1261-1266.
40. Bernard J., Yi E.S. Pulmonary thromboendarterectomy: a clinicopathologic study of 200 consecutive pulmonary thromboendarterectomy cases in one institution. Hum Pathol 2007, 38:871-877.
41. Ina Y., Takada K., Yamamoto M., Sato T., Ito S., Sato S. Antiphospholipid antibodies. A prognostic factor in sarcoidosis?. Chest 1994, 105:1179-1183.
42. Wesemann D.R., Costenbader K.H., Coblyn J.S. Co-existing sarcoidosis, systemic lupus erythematosus and the antiphospholipid antibody syndrome: case reports and discussion from the Brigham and Women's Hospital Lupus Center. Lupus 2009, 18:202-205.
43. Carragoso A., Silva J.R., Capelo J., Faria B., Gaspar O. A patient with sarcoidosis and antiphospholipid syndrome. Eur J Intern Med 2008, 19:e80-e81.
44. Takahashi F., Toba M., Takahashi K., et al. Pulmonary sarcoidosis and antiphospholipid syndrome. Respirology 2006, 11:506-508.
45. Ishii A., Hoshii Y., Nakashima T., et al. Sarcoidosis with pulmonary hypertension exacerbated by Takayasu-like large vessel vasculitis. Pathol Int 2011, 61:546-550.
46. Bandt M.D., Meyer O., Masson C., Peroux-Goumy L., Audran M., Kahn M.F. Systemic scleroderma and sarcoidosis: 3 new cases. Ann Med Interne (Paris) 1996, 147:590-594.
47. Turner G.A., Lower E.E., Corser B.C., Gunther K.L., Baughman R.P. Sleep apnea in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997, 14:61-64.
48. Verbraecken J., Hoitsma E., van der Grinten C.P., Cobben N.A., Wouters E.F., Drent M. Sleep disturbances associated with periodic leg movements in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004, 21:137-146.
49. Arcasoy S.M., Christie J.D., Ferrari V.A., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003, 167:735-740.
50. Nathan S.D., Shlobin O.A., Barnett S.D., et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008, 102:1305-1310.
51. Zisman D.A., Ross D.J., Belperio J.A., et al. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2007, 101:2153-2159.
52. Hamada K., Nagai S., Tanaka S., et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007, 131:650-656.
53. Corte T.J., Wort S.J., Gatzoulis M.A., Macdonald P., Hansell D.M., Wells A.U. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax 2009, 64:883-888.
54. Chang B., Wigley F.M., White B., Wise R.A. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003, 30:2398-2405.
55. Steen V.D., Graham G., Conte C., Owens G., Medsger T.A. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992, 35:765-770.
56. Trad S., Amoura Z., Beigelman C., et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006, 54:184-191.
57. Nathan S.D., Shlobin O.A., Ahmad S., Urbanek S., Barnett S.D. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007, 131:657-663.
58. Zisman D.A., Karlamangla A.S., Kawut S.M., et al. Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2008, 133:640-645.
59. Baughman R.P., Sparkman B.K., Lower E.E. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007, 132:207-213.
60. Zisman D.A., Karlamangla A.S., Ross D.J., et al. High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2007, 132:773-779.
61. Devaraj A., Wells A.U., Meister M.G., Corte T.J., Hansell D.M. The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. Radiology 2008, 249:1042-1049.
62. Leuchte H.H., Neurohr C., Baumgartner R., et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004, 170:360-365.
63. Leuchte H.H., Baumgartner R.A., Nounou M.E., et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006, 173:744-750.
64. Corte T.J., Wort S.J., Gatzoulis M.A., et al. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J 2010, 36:819-825.
65. Song J.W., Song J.K., Kim D.S. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med 2009, 103:180-186.
66. Handa T., Nagai S., Ueda S., et al. Significance of plasma NT-proBNP levels as a biomarker in the assessment of cardiac involvement and pulmonary hypertension in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010, 27:27-35.
67. Culver D.A., Krasuski R.A. Right-sided heart catheterization: de rigueur in sarcoidosis. Chest 2010, 138:1030-1032.
68. Arcasoy S.M., Christie J.D., Pochettino A., et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001, 120:873-880.
69. Shorr A.F., Davies D.B., Nathan S.D. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003, 124:922-928.
70. Nardi A., Brillet P.Y., Letoumelin P., et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011, 38:1368-1373.
71. Barst R.J., Ratner S.J. Sarcoidosis and reactive pulmonary hypertension. Arch Intern Med 1985, 145:2112-2114.
72. Damuth T.E., Bower J.S., Cho K., Dantzker D.R. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis. Chest 1980, 78:888-891.
73. Portier F., Lerebours-Pigeonniere G., Thiberville L., et al. Sarcoidosis simulating a pulmonary veno-occlusive disease. Rev Mal Respir 1991, 8:101-102.
74. Smith L.J., Lawrence J.B., Katzenstein A.A. Vascular sarcoidosis: a rare cause of pulmonary hypertension. Am J Med Sci 1983, 285:38-44.
75. Gluskowski J., Hawrylkiewicz I., Zych D., Zielinski J. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J 1990, 3:403-407.
76. Davies J., Nellen M., Goodwin J.F. Reversible pulmonary hypertension in sarcoidosis. Postgrad Med J 1982, 58:282-285.
77. Rodman D.M., Lindenfeld J. Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids. Chest 1990, 97:500-502.
78. Olschewski H., Ghofrani H.A., Walmrath D., et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999, 160:600-607.
79. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002, 360:895-900.
80. Gunther A., Enke B., Markart P., et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur Respir J 2007, 29:713-719.
81. Baughman R.P., Judson M.A., Lower E.E., et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009, 26:110-120.
82. Minai O.A., Sahoo D., Chapman J.T., Mehta A.C. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir Med 2008, 102:1015-1020.
83. Milman N., Burton C.M., Iversen M., Videbaek R., Jensen C.V., Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil. J Heart Lung Transplant 2008, 27:329-334.
84. Corte T.J., Gatzoulis M.A., Parfitt L., Harries C., Wells A.U., Wort S.J. The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. Respirology 2010, 15:1226-1232.
85. Judson M.A., Highland K.B., Kwon S., et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2011, 28:139-145.